On August 5, 2019, the SEC filed an emergency action against Arbutus Biopharma Corp. ("AB-506") and its CEO, Bill Collier, for acting as unregistered brokers in the company's hepatitis B clinical trial.  The SEC's complaint alleges that AB-506 and AB-729 violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  According to the complaint, AB-506 and AB-729 are potent oral capsid inhibitors with the potential to significantly reduce the number of hepatitis B patients who are infected with the virus.  The complaint further alleges that AB-506 and AB-729 are a potent captive inhibitors and warrants further development.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, charges Bill with violating the antifraud provisions of Section 17(b) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and seeks disgorgement of ill-gotten gains plus interest, penalties, and injunctive relief.  The SEC's investigation was conducted by Keay Nakae, Chardan Patricia Tan, and Patricia Tan, and supervised by Kelly L. Gibson.  The litigation will be led by Kelly L. Gibson.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York and the Federal Bureau of Investigation.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.  The SEC encourages investors to check the backgrounds of people selling or offering investments by using theÂ Investor.govÂ to quickly identify whether they are registered professionals.